Bicara Therapeutics Inc. BCAX
Set alert
9.31 USD +1.38 +17.34%
As of Nov 3, 11:22 AM ET
7.90 Day range 9.35
7.87 52-week range 30.99
- YTD
- -44.71%
- 1 year
- -41.77%
- Open
- 8.03
- Prev close
- 7.93
- Mkt cap
- 616.07M
- Vol
- 535.90K
- Avg vol
- 1.06M
- EPS
- -3.08
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.90
- High
- 9.35
- Forward P/E
- -4.96
- Beta
- -0.69
- Short ratio
- 16.85
- Inst. own
- 102.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 20.82
- 200-d avg
- 21.33
- 1y target
- 35.67
5Y chart
Events in this range
- Aug 12, 2025Earnings: -0.5; estimate -0.54; surprise 7.41%
- Nov 10, 2025Earnings: -0.67; estimate -0.55; surprise -21.82%
- Mar 26, 2026Earnings: -0.68; estimate -0.72; surprise 5.56%
- May 11, 2026Earnings: -0.93; estimate -0.64; surprise -45.31%
- Aug 11, 2026Earnings: -0.82; estimate -0.81978; surprise -0.03%
- Aug 12, 2026Rating: Mizuho · Neutral → Neutral
- Aug 12, 2026Rating: Morgan Stanley · Overweight → Overweight
- Aug 12, 2026Rating: Wedbush · Outperform → Outperform
- Aug 12, 2026Rating: Goldman Sachs · Neutral → Neutral
- Aug 19, 2026Rating: BMO Capital · — → Outperform
- Oct 19, 2026Rating: BTIG · Buy → Buy
- Nov 9, 2026Earnings: —; estimate -0.84; surprise —%
Signals (38)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 26, 2026 | 1 week ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| RSI: Overbought | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| RSI: Overbought | Apr 13, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 9, 2026 | 7 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| SMA: Bullish | Feb 16, 2026 | 8 months ago |
| SMA: Bearish | Feb 9, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 19, 2026 | 9 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Jan 5, 2026 | 10 months ago |
| SMA: Bearish | Dec 22, 2025 | 10 months ago |
Newest 20 of 38.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 35.67 +283.3% upside
Now 9.31
- Target (low)
- 20.00
- Target (mean)
- 35.67
- Target (high)
- 45.00
Ratings (0m) 14 13 buy · 1 hold · 0 sell
- Strong buy3
- Buy10
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 14
- 1 month ago 14
- 2 months ago 16
- 3 months ago 15
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.82167 | -0.97 – -0.42 | -0.67 | -22.6% | 0 | 0.0% | 12 |
| Next quarter | -0.85417 | -0.97 – -0.47 | -0.68 | -25.6% | 0 | 0.0% | 12 |
| Current year | -3.39 | -3.68 – -2.65 | -2.52 | -34.4% | 0 | 0.0% | 12 |
| Next year | -3.52 | -4.73 – -1.86 | -3.39 | -4.0% | 0 | 0.0% | 11 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | BTIG | Reiterated | Buy | Buy |
| Aug 19, 2026 | BMO Capital | Initiated | — | Outperform |
| Aug 12, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Aug 12, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Aug 12, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 12, 2026 | Mizuho | Maintained | Neutral | Neutral |
| Aug 12, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Aug 12, 2026 | BTIG | Maintained | Buy | Buy |
| May 12, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| May 12, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 11, 2026 | Guggenheim | Initiated | — | Buy |
| Mar 31, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Mar 31, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Mar 31, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Mar 31, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Mar 31, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 25, 2026 | B of A Securities | Initiated | — | Buy |
| Jan 29, 2026 | Citizens | Initiated | — | Market Outperform |
| Jan 13, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Jan 8, 2026 | BTIG | Initiated | — | Buy |
| Dec 18, 2025 | Mizuho | Initiated | — | Neutral |
| Nov 11, 2025 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Aug 22, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 19, 2025 | Piper Sandler | Initiated | — | Overweight |
| May 23, 2025 | Wells Fargo | Upgrade | Underweight | Equal-Weight |
| May 16, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 17, 2025 | Wells Fargo | Initiated | — | Underweight |
| Apr 7, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 13, 2025 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Feb 12, 2025 | Wedbush | Reiterated | Outperform | Outperform |